Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.56 |
| ▸ | CTSB | P07858 | 2/20 | 0.56 |
| ▸ | CTSS | P25774 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CTSK | P43235 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CASP3 | P42574 | 2/20 | 0.47 |
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
| ▸ | MME | P08473 | 1/20 | 0.46 |
| ▸ | ECE1 | P42892 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22346389 | 1.00 | CTSL (0.56) | CTSLCTSBCTSSCYP3A4CYP2D6 | |
| SCHEMBL14502789 | 1.00 | CTSL (0.56) | CTSLCTSBCTSSCYP3A4CYP2D6 | |
| SCHEMBL29619298 | 0.87 | LMNA (0.48) | CTSLCTSBCTSSCYP3A4CYP2D6 | |
| SCHEMBL22346392 | 0.87 | CTSL (0.55) | CTSLCTSBCTSSCYP3A4CYP2D6 | |
| SCHEMBL22346420 | 0.87 | CTSL (0.55) | CTSLCTSBCTSSCYP3A4CYP2D6 | |
| SCHEMBL22346418 | 0.87 | CTSL (0.55) | CTSLCTSBCTSSCYP3A4CYP2D6 | |
| SCHEMBL22346390 | 0.87 | CTSL (0.55) | CTSLCTSBCTSSCYP3A4CYP2D6 | |
| SCHEMBL21444755 | 0.86 | ALDH1A1 (0.50) | CTSLCTSBCTSSCYP3A4CYP2D6 | |
| SCHEMBL6959620 | 0.86 | ALDH1A1 (0.53) | CTSLCTSBCTSSMEN1KMT2A | |
| SCHEMBL8707008 | 0.86 | ALDH1A1 (0.53) | CTSLCTSBCTSSMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230132386-A9 | GRANZYME B DIRECTED IMAGING AND THERAPY | CYTOSITE BIOPHARMA INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230132386-A9 | GRANZYME B DIRECTED IMAGING AND THERAPY | CYTOSITE BIOPHARMA INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230132386-A9 | GRANZYME B DIRECTED IMAGING AND THERAPY | CYTOSITE BIOPHARMA INC. | 2023-04-27 | — | — | US | disclosed |
| US-20220135593-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | CYTOSITE BIOPHARMA INC (US) | 2022-05-05 | — | — | US | disclosed |
| US-20220135593-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | CYTOSITE BIOPHARMA INC (US) | 2022-05-05 | — | — | US | disclosed |
| EP-3924354-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | Cytosite Biopharma Inc. (US) | 2021-12-22 | — | — | EP | disclosed |
| WO-2020167989-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | CYTOSITE BIOPHARMA INC. (US) | 2020-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230132386-A9 | GRANZYME B DIRECTED IMAGING AND THERAPY | GZMB, PRF1, CTSB | CTSL 87/4885CTSB 3/4885CTSS 65/4885 |
| US-20220135593-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | GZMB, PRF1, CTSB | CTSL 87/4885CTSB 3/4885CTSS 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.